Young brings over 20 years of finance and capital markets experience, a background in financial planning and operations, management and strategy, and knowledge of the life sciences sector.
In addition, Axial Biotherapeutics also appointed Dennis Yamashita, Ph.D., as vice president, medicinal chemistry.
Young most recently served as CFO, treasurer and secretary at Juniper Pharmaceuticals, Inc., where he played an instrumental role in Juniper's acquisition by Catalent.
Prior to that, Young served as CFO and treasurer of OvaScience, a global fertility company focused on new treatment options for women. Young was previously the CFO and treasurer of Transmedics, a developer of medical devices for the maintenance and transport of organs between donors and recipients.
Before that, he served as CFO and treasurer at Lantheus Medical Imaging, where he led and managed multiple public debt offerings.
Young began his career holding various positions of increasing responsibility in finance at Critical Therapeutics, PerkinElmer, Inc. and PriceWaterhouseCoopers LLP. Young holds a Bachelor of Science in Business Administration from Georgetown University.
Yamashita is an experienced drug developer and medicinal chemist with leadership experience at GSK and in biotech.
Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials